PedAM

Pediatric Disease Annotations & Medicines


	urticaria

Disease ID	525
Disease	urticaria
Definition	A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.
Synonym	(urticaria nos) or (hives) (urticaria nos) or (hives) (disorder) hive hived hives hives nos hiving nettle rash nettles rash rash nettle rash urticarial urticaria (disorder) urticaria (morphologic abnormality) urticaria [disease/finding] urticaria nos urticaria nos (disorder) urticaria, unspecified urticarial urticarial rash urticarias welt
DOID	DOID:1555
ICD10	ICD10CM:L50.9
UMLS	C0042109
MeSH	D014581
SNOMED-CT	SNOMEDCT_US_2016_09_01:126485001
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:75) C0011603 \| dermatitis \| 5 C0004096 \| asthma \| 5 C0015230 \| rash \| 5 C0042109 \| hives \| 3 C0042384 \| vasculitis \| 3 C0037274 \| skin disease \| 3 C0011570 \| depression \| 2 C0040553 \| toxocariasis \| 2 C0157741 \| idiopathic urticaria \| 2 C0011615 \| atopic dermatitis \| 2 C0019348 \| herpes simplex \| 2 C0021053 \| immune disorders \| 2 C0343065 \| dermatographism \| 2 C0024530 \| malaria \| 2 C0007570 \| celiac disease \| 2 C0021053 \| immune disorder \| 2 C0035455 \| rhinitis \| 2 C0004623 \| bacterial infection \| 2 C0920350 \| autoimmune thyroiditis \| 2 C0085253 \| adult-onset still's disease \| 2 C0019342 \| genital herpes \| 2 C0019348 \| herpes simplex infection \| 2 C2607914 \| allergic rhinitis \| 1 C0018023 \| nodular goiter \| 1 C0004096 \| bronchial asthma \| 1 C0016470 \| food allergies \| 1 C0152230 \| cholinergic urticaria \| 1 C0026896 \| myasthenia gravis \| 1 C0033860 \| psoriasis \| 1 C0040147 \| thyroiditis \| 1 C0023890 \| hepatic cirrhosis \| 1 C0042109 \| urticarial \| 1 C0003028 \| anhidrosis \| 1 C0026934 \| mycoplasma \| 1 C0024897 \| mastocytoma \| 1 C0035078 \| renal failure \| 1 C0004779 \| nevoid basal cell carcinoma syndrome \| 1 C0238463 \| papillary thyroid carcinoma \| 1 C0020598 \| hypoglycemia \| 1 C0162576 \| anisakiasis \| 1 C1136033 \| cutaneous mastocytosis \| 1 C0013595 \| eczema \| 1 C0023346 \| borderline leprosy \| 1 C0549473 \| thyroid carcinoma \| 1 C0039128 \| syphilis \| 1 C0007133 \| papillary carcinoma \| 1 C0036117 \| salmonella infection \| 1 C0020676 \| hypothyroid \| 1 C0023267 \| leiomyomas \| 1 C0019342 \| genital herpes simplex \| 1 C0042133 \| uterine leiomyoma \| 1 C0042769 \| virus infection \| 1 C0016470 \| food allergy \| 1 C0007117 \| basal cell carcinoma \| 1 C0023343 \| leprosy \| 1 C0021053 \| immune disease \| 1 C0004623 \| bacterial infections \| 1 C0037274 \| skin conditions \| 1 C0035204 \| respiratory disease \| 1 C0149931 \| migraine \| 1 C0037199 \| sinusitis \| 1 C0037274 \| skin diseases \| 1 C0085113 \| neurofibromatosis \| 1 C0162820 \| allergic contact dermatitis \| 1 C0018021 \| goiter \| 1 C0524988 \| schnitzler syndrome \| 1 C0031542 \| phlebitis \| 1 C0238463 \| thyroid papillary carcinoma \| 1 C0022951 \| lactose intolerance \| 1 C0036117 \| salmonella infect \| 1 C0007115 \| thyroid ca \| 1 C0019158 \| hepatitis \| 1 C0011616 \| contact dermatitis \| 1 C0577620 \| nut allergy \| 1 C0376358 \| prostate cancer \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:16) HLA-DRB1 \| 3123 \| CTD_human TNF \| 7124 \| CTD_human ICAM1 \| 3383 \| CTD_human TGFB1 \| 7040 \| CTD_human VCAM1 \| 7412 \| CTD_human IL1B \| 3553 \| CTD_human HLA-DPB1 \| 3115 \| CTD_human ALB \| 213 \| CTD_human HLA-DQB1 \| 3119 \| CTD_human SELE \| 6401 \| CTD_human HNMT \| 3176 \| CTD_human ALOX5 \| 240 \| CTD_human MPO \| 4353 \| CTD_human IL18 \| 3606 \| CTD_human GSTM1 \| 2944 \| CTD_human FCER1A \| 2205 \| CTD_human
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:11) 154 \| ADRB2 \| infer 2358 \| FPR2 \| infer 3105 \| HLA-A \| infer 3106 \| HLA-B \| infer 3107 \| HLA-C \| infer 3117 \| HLA-DQA1 \| infer 3119 \| HLA-DQB1 \| infer 3123 \| HLA-DRB1 \| infer 3176 \| HNMT \| infer 7040 \| TGFB1 \| infer 7124 \| TNF \| infer
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:244) 104940698 \| DALIR \| DISEASES 51087 \| YBX2 \| DISEASES 7132 \| TNFRSF1A \| DISEASES 30009 \| TBX21 \| DISEASES 49 \| ACR \| DISEASES 5816 \| PVALB \| DISEASES 1511 \| CTSG \| DISEASES 2158 \| F9 \| DISEASES 479 \| ATP12A \| DISEASES 6361 \| CCL17 \| DISEASES 4210 \| MEFV \| DISEASES 7038 \| TG \| DISEASES 8797 \| TNFRSF10A \| DISEASES 973 \| CD79A \| DISEASES 64598 \| MOSPD3 \| DISEASES 4353 \| MPO \| DISEASES 8288 \| EPX \| DISEASES 6347 \| CCL2 \| DISEASES 5197 \| PF4V1 \| DISEASES 3558 \| IL2 \| DISEASES 4254 \| KITLG \| DISEASES 6404 \| SELPLG \| DISEASES 3458 \| IFNG \| DISEASES 50813 \| COPS7A \| DISEASES 705 \| BYSL \| DISEASES 3565 \| IL4 \| DISEASES 3567 \| IL5 \| DISEASES 1933 \| EEF1B2 \| DISEASES 80306 \| MED28 \| DISEASES 51426 \| POLK \| DISEASES 54800 \| KLHL24 \| DISEASES 718 \| C3 \| DISEASES 22918 \| CD93 \| DISEASES 968 \| CD68 \| DISEASES 6320 \| CLEC11A \| DISEASES 1215 \| CMA1 \| DISEASES 3630 \| INS \| DISEASES 54795 \| TRPM4 \| DISEASES 2161 \| F12 \| DISEASES 3958 \| LGALS3 \| DISEASES 6737 \| TRIM21 \| DISEASES 1401 \| CRP \| DISEASES 1830 \| DSG3 \| DISEASES 967 \| CD63 \| DISEASES 51719 \| CAB39 \| DISEASES 3569 \| IL6 \| DISEASES 3557 \| IL1RN \| DISEASES 26525 \| IL36RN \| DISEASES 5082 \| PDCL \| DISEASES 10850 \| CCL27 \| DISEASES 28234 \| SLCO1B3 \| DISEASES 4069 \| LYZ \| DISEASES 114294 \| LACTB \| DISEASES 51816 \| CECR1 \| DISEASES 495 \| ATP4A \| DISEASES 7224 \| TRPC5 \| DISEASES 1109 \| AKR1C4 \| DISEASES 3552 \| IL1A \| DISEASES 3553 \| IL1B \| DISEASES 1991 \| ELANE \| DISEASES 56902 \| PNO1 \| DISEASES 6403 \| SELP \| DISEASES 3299 \| HSF4 \| DISEASES 2208 \| FCER2 \| DISEASES 1371 \| CPOX \| DISEASES 8808 \| IL1RL2 \| DISEASES 84961 \| FBXL20 \| DISEASES 3818 \| KLKB1 \| DISEASES 5443 \| POMC \| DISEASES 3383 \| ICAM1 \| DISEASES 3827 \| KNG1 \| DISEASES 7365 \| UGT2B10 \| DISEASES 7375 \| USP4 \| DISEASES 3700 \| ITIH4 \| DISEASES 55040 \| EPN3 \| DISEASES 10550 \| ARL6IP5 \| DISEASES 9180 \| OSMR \| DISEASES 1392 \| CRH \| DISEASES 710 \| SERPING1 \| DISEASES 6749 \| SSRP1 \| DISEASES 2206 \| MS4A2 \| DISEASES 3176 \| HNMT \| DISEASES 3606 \| IL18 \| DISEASES 51594 \| NBAS \| DISEASES 84539 \| MCHR2 \| DISEASES 57105 \| CYSLTR2 \| DISEASES 25890 \| ABI3BP \| DISEASES 3815 \| KIT \| DISEASES 539 \| ATP5O \| DISEASES 715 \| C1R \| DISEASES 57519 \| STARD9 \| DISEASES 1636 \| ACE \| DISEASES 84303 \| CHCHD6 \| DISEASES 4056 \| LTC4S \| DISEASES 114757 \| CYGB \| DISEASES 6352 \| CCL5 \| DISEASES 6006 \| RHCE \| DISEASES 7412 \| VCAM1 \| DISEASES 2215 \| FCGR3B \| DISEASES 23498 \| HAAO \| DISEASES 152185 \| SPICE1 \| DISEASES 213 \| ALB \| DISEASES 5473 \| PPBP \| DISEASES 5196 \| PF4 \| DISEASES 3562 \| IL3 \| DISEASES 1437 \| CSF2 \| DISEASES 3636 \| INPPL1 \| DISEASES 717 \| C2 \| DISEASES 92292 \| GLYATL1 \| DISEASES 3906 \| LALBA \| DISEASES 94274 \| PPP1R14A \| DISEASES 23524 \| SRRM2 \| DISEASES 6356 \| CCL11 \| DISEASES 6037 \| RNASE3 \| DISEASES 5734 \| PTGER4 \| DISEASES 116984 \| ARAP2 \| DISEASES 23179 \| RGL1 \| DISEASES 6036 \| RNASE2 \| DISEASES 3596 \| IL13 \| DISEASES 8625 \| RFXANK \| DISEASES 64805 \| P2RY12 \| DISEASES 2147 \| F2 \| DISEASES 9092 \| SART1 \| DISEASES 51172 \| NAGPA \| DISEASES 388403 \| YPEL2 \| DISEASES 64236 \| PDLIM2 \| DISEASES 931 \| MS4A1 \| DISEASES 7173 \| TPO \| DISEASES 91662 \| NLRP12 \| DISEASES 27181 \| SIGLEC8 \| DISEASES 6863 \| TAC1 \| DISEASES 5345 \| SERPINF2 \| DISEASES 79054 \| TRPM8 \| DISEASES 2 \| A2M \| DISEASES 57010 \| CABP4 \| DISEASES 9622 \| KLK4 \| DISEASES 2318 \| FLNC \| DISEASES 3563 \| IL3RA \| DISEASES 716 \| C1S \| DISEASES 84876 \| ORAI1 \| DISEASES 6401 \| SELE \| DISEASES 113179 \| ADAT3 \| DISEASES 117194 \| MRGPRX2 \| DISEASES 2152 \| F3 \| DISEASES 9376 \| SLC22A8 \| DISEASES 114548 \| NLRP3 \| DISEASES 7360 \| UGP2 \| DISEASES 85480 \| TSLP \| DISEASES 1308 \| COL17A1 \| DISEASES 5132 \| PDC \| DISEASES 6633 \| SNRPD2 \| DISEASES 921 \| CD5 \| DISEASES 3605 \| IL17A \| DISEASES 538 \| ATP7A \| DISEASES 728 \| C5AR1 \| DISEASES 4983 \| OPHN1 \| DISEASES 5265 \| SERPINA1 \| DISEASES 1822 \| ATN1 \| DISEASES 3683 \| ITGAL \| DISEASES 5350 \| PLN \| DISEASES 5169 \| ENPP3 \| DISEASES 5336 \| PLCG2 \| DISEASES 3635 \| INPP5D \| DISEASES 26191 \| PTPN22 \| DISEASES 11169 \| WDHD1 \| DISEASES 5742 \| PTGS1 \| DISEASES 10724 \| MGEA5 \| DISEASES 4283 \| CXCL9 \| DISEASES 58 \| ACTA1 \| DISEASES 7432 \| VIP \| DISEASES 5743 \| PTGS2 \| DISEASES 1805 \| DPT \| DISEASES 2214 \| FCGR3A \| DISEASES 2205 \| FCER1A \| DISEASES 7390 \| UROS \| DISEASES 2312 \| FLG \| DISEASES 914 \| CD2 \| DISEASES 4803 \| NGF \| DISEASES 140 \| ADORA3 \| DISEASES 2316 \| FLNA \| DISEASES 1369 \| CPN1 \| DISEASES 255631 \| COL24A1 \| DISEASES 959 \| CD40LG \| DISEASES 5236 \| PGM1 \| DISEASES 6342 \| SCP2 \| DISEASES 7422 \| VEGFA \| DISEASES 10800 \| CYSLTR1 \| DISEASES 80114 \| BICC1 \| DISEASES 240 \| ALOX5 \| DISEASES 3339 \| HSPG2 \| DISEASES 2155 \| F7 \| DISEASES 6850 \| SYK \| DISEASES 23013 \| SPEN \| DISEASES 50943 \| FOXP3 \| DISEASES 7133 \| TNFRSF1B \| DISEASES 7454 \| WAS \| DISEASES 386653 \| IL31 \| DISEASES 3274 \| HRH2 \| DISEASES 23177 \| CEP68 \| DISEASES 5212 \| VIT \| DISEASES 2625 \| GATA3 \| DISEASES 55003 \| PAK1IP1 \| DISEASES 241 \| ALOX5AP \| DISEASES 54796 \| BNC2 \| DISEASES 90865 \| IL33 \| DISEASES 238 \| ALK \| DISEASES 1130 \| LYST \| DISEASES 114805 \| GALNT13 \| DISEASES 347734 \| SLC35B2 \| DISEASES 5627 \| PROS1 \| DISEASES 3269 \| HRH1 \| DISEASES 4689 \| NCF4 \| DISEASES 594857 \| NPS \| DISEASES 3119 \| HLA-DQB1 \| DISEASES 24144 \| TFIP11 \| DISEASES 6915 \| TBXA2R \| DISEASES 197 \| AHSG \| DISEASES 85443 \| DCLK3 \| DISEASES 720 \| C4A \| DISEASES 117579 \| RLN3 \| DISEASES 7124 \| TNF \| DISEASES 9278 \| ZBTB22 \| DISEASES 2145 \| EZH1 \| DISEASES 834 \| CASP1 \| DISEASES 3586 \| IL10 \| DISEASES 629 \| CFB \| DISEASES 51428 \| DDX41 \| DISEASES 23194 \| FBXL7 \| DISEASES 22999 \| RIMS1 \| DISEASES 7178 \| TPT1 \| DISEASES 56 \| ACRV1 \| DISEASES 26298 \| EHF \| DISEASES 727897 \| MUC5B \| DISEASES 930 \| CD19 \| DISEASES 83695 \| RHNO1 \| DISEASES 1232 \| CCR3 \| DISEASES 4637 \| MYL6 \| DISEASES 387521 \| TMEM189 \| DISEASES 84839 \| RAX2 \| DISEASES 23186 \| RCOR1 \| DISEASES 162514 \| TRPV3 \| DISEASES 25804 \| LSM4 \| DISEASES 57000 \| GSN-AS1 \| DISEASES 102723508 \| KANTR \| DISEASES
Locus	(Waiting for update.)

Disease ID	525
Disease	urticaria
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:56) HP:0100665 \| Angiooedema \| 25 HP:0000989 \| pruritis \| 9 HP:0000966 \| Decreased sweating \| 6 HP:0012393 \| Allergy \| 6 HP:0002099 \| Asthma \| 5 HP:0002960 \| Autoimmune condition \| 4 HP:0002615 \| Low blood pressure \| 4 HP:0000969 \| Dropsy \| 3 HP:0001025 \| Hives \| 3 HP:0002633 \| Vasculitis \| 3 HP:0012384 \| Nasal inflammation \| 2 HP:0000716 \| Depression \| 2 HP:0001945 \| Fever \| 2 HP:0010783 \| Erythema \| 2 HP:0002895 \| Papillary thyroid carcinoma \| 2 HP:0002608 \| Celiac disease \| 2 HP:0011971 \| Dermatographism \| 2 HP:0001047 \| Atopic dermatitis \| 2 HP:0000958 \| Xerosis \| 1 HP:0000975 \| Increased sweating \| 1 HP:0100570 \| Carcinoid tumor \| 1 HP:0005764 \| Polyarticular arthritis \| 1 HP:0002958 \| Immune dysregulation \| 1 HP:0000083 \| Renal insufficiency \| 1 HP:0002664 \| Neoplasia \| 1 HP:0001880 \| Eosinophilia \| 1 HP:0001943 \| Hypoglycemia \| 1 HP:0030828 \| Wheezing \| 1 HP:0000980 \| Pallor \| 1 HP:0002890 \| Thyroid carcinoma \| 1 HP:0003193 \| Allergic rhinitis \| 1 HP:0100845 \| Anaphylactic shock \| 1 HP:0001394 \| Hepatic cirrhosis \| 1 HP:0200151 \| Cutaneous mastocytosis \| 1 HP:0000246 \| Sinus inflammation \| 1 HP:0002671 \| Basalioma \| 1 HP:0002076 \| Migraine headaches \| 1 HP:0003473 \| Fatigable weakness \| 1 HP:0002013 \| Emesis \| 1 HP:0002829 \| Arthralgias \| 1 HP:0012115 \| Liver inflammation \| 1 HP:0003765 \| Psoriasis \| 1 HP:0005994 \| Nodular goiter \| 1 HP:0000131 \| Uterine leiomyoma \| 1 HP:0000964 \| Eczema \| 1 HP:0004789 \| Lactose intolerance \| 1 HP:0002098 \| Respiratory distress \| 1 HP:0002094 \| Dyspnea \| 1 HP:0000853 \| Goitre \| 1 HP:0030445 \| Lung carcinoid tumor \| 1 HP:0100646 \| Thyroiditis \| 1 HP:0002018 \| Nausea \| 1 HP:0000970 \| Lack of sweating \| 1 HP:0000988 \| Exanthem \| 1 HP:0001067 \| Neurofibromas \| 1 HP:0012125 \| Prostate cancer \| 1

Disease ID	525
Disease	urticaria
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:7) C0033774 \| pruritus \| 9 C0221232 \| wheals \| 5 C0033774 \| itching \| 3 C0042769 \| virus infection \| 1 C0016470 \| food allergy \| 1 C0014457 \| eosinophilia \| 1 C0016470 \| food allergies \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:2)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs11673309	25455139	728	C5AR1	umls:C0042109	BeFree	Influence of component 5a receptor 1 (C5AR1) -1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria.	0.000271442	2014	C5AR1	19	47308566	T	G
rs730012	19862937	4056	LTC4S	umls:C0042109	BeFree	The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria.	0.002909916	2009	LTC4S	5	179793637	A	C

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:68)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0042109	acetaminophen	D000082	103-90-2	urticaria	MESH:D014581	marker/mechanism	10400483
C0042109	allopurinol	D000493	315-30-0	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	amcinonide	C012716	-	urticaria	MESH:D014581	marker/mechanism	8449700
C0042109	amiloride	D000584	2609-46-3	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	aminoglutethimide	D000616	125-84-8	urticaria	MESH:D014581	marker/mechanism	7274074
C0042109	azithromycin	D017963	83905-01-5	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	aztreonam	D001398	78110-38-0	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	caffeine	D002110	1958/8/2	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	carbamazepine	D002220	298-46-4	urticaria	MESH:D014581	marker/mechanism	3824622
C0042109	carbenicillin	D002228	4697-36-3	urticaria	MESH:D014581	marker/mechanism	6176609
C0042109	carbimazole	D002231	22232-54-8	urticaria	MESH:D014581	marker/mechanism	15785249
C0042109	cefotaxime	D002439	63527-52-6	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	ceftazidime	D002442	78439-06-2	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	celecoxib	D000068579	-	urticaria	MESH:D014581	marker/mechanism	11476468
C0042109	cephalexin	D002506	15686-71-2	urticaria	MESH:D014581	marker/mechanism	15365421
C0042109	cetirizine	D017332	83881-51-0	urticaria	MESH:D014581	therapeutic	11034010
C0042109	cimetidine	D002927	51481-61-9	urticaria	MESH:D014581	marker/mechanism	6638053
C0042109	cimetidine	D002927	51481-61-9	urticaria	MESH:D014581	therapeutic	2404434
C0042109	ciprofloxacin	D002939	85721-33-1	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	clemastine	D002974	15686-51-8	urticaria	MESH:D014581	therapeutic	2569997
C0042109	dapsone	D003622	80-08-0	urticaria	MESH:D014581	therapeutic	2985516
C0042109	diatrizoate	D003973	117-96-4	urticaria	MESH:D014581	marker/mechanism	2917833
C0042109	diclofenac	D004008	15307-86-5	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	dicloxacillin	D004009	3116-76-5	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	diltiazem	D004110	42399-41-7	urticaria	MESH:D014581	marker/mechanism	3120959
C0042109	etomidate	D005045	33125-97-2	urticaria	MESH:D014581	marker/mechanism	2675669
C0042109	fenoprofen	D005279	31879-05-7	urticaria	MESH:D014581	marker/mechanism	1115460
C0042109	fluoxetine	D005473	54910-89-3	urticaria	MESH:D014581	marker/mechanism	2628588
C0042109	hydroxocobalamin	D006879	13422-51-0	urticaria	MESH:D014581	marker/mechanism	5572387
C0042109	hydroxyzine	D006919	68-88-2	urticaria	MESH:D014581	therapeutic	1683191
C0042109	indomethacin	D007213	53-86-1	urticaria	MESH:D014581	marker/mechanism	1115460
C0042109	ketorolac	D020910	66635-83-4	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	lansoprazole	D064747	-	urticaria	MESH:D014581	marker/mechanism	12464168
C0042109	lidocaine	D008012	137-58-6	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	loratadine	D017336	79794-75-5	urticaria	MESH:D014581	therapeutic	10188144
C0042109	lovastatin	D008148	75330-75-5	urticaria	MESH:D014581	marker/mechanism	10084510
C0042109	mefloquine	D015767	53230-10-7	urticaria	MESH:D014581	marker/mechanism	10457122
C0042109	meloxicam	C065757	71125-38-7	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	meprobamate	D008620	57-53-4	urticaria	MESH:D014581	marker/mechanism	5092569
C0042109	montelukast	C093875	158966-92-8	urticaria	MESH:D014581	therapeutic	10982225
C0042109	nevirapine	D019829	129618-40-2	urticaria	MESH:D014581	marker/mechanism	12738113
C0042109	ofloxacin	D015242	82419-36-1	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	omeprazole	D009853	73590-58-6	urticaria	MESH:D014581	marker/mechanism	12464168
C0042109	pefloxacin	D015366	70458-92-3	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	phenindione	D010630	1983/12/5	urticaria	MESH:D014581	marker/mechanism	4248923
C0042109	phenylpropanolamine	D010665	14838-15-4	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	piperacillin	D010878	61477-96-1	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	piroxicam	D010894	36322-90-4	urticaria	MESH:D014581	marker/mechanism	10982225
C0042109	propylthiouracil	D011441	51-52-5	urticaria	MESH:D014581	marker/mechanism	14530534
C0042109	ramipril	D017257	87333-19-5	urticaria	MESH:D014581	marker/mechanism	12780733
C0042109	rifampin	D012293	13292-46-1	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	rifaximin	C042734	-	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	succinylcholine	D013390	306-40-1	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	sulfadiazine	D013411	68-35-9	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	tenoxicam	C032801	59804-37-4	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	terfenadine	D016593	50679-08-8	urticaria	MESH:D014581	therapeutic	2565098
C0042109	thalidomide	D013792	50-35-1	urticaria	MESH:D014581	marker/mechanism	2985516
C0042109	thiopental	D013874	76-75-5	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	ticlopidine	D013988	55142-85-3	urticaria	MESH:D014581	marker/mechanism	8855878
C0042109	tinidazole	D014011	19387-91-8	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	tolmetin	D014046	26171-23-3	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	valdecoxib	C406224	-	urticaria	MESH:D014581	marker/mechanism	15702813
C0042109	vancomycin	D014640	1404-90-6	urticaria	MESH:D014581	marker/mechanism	3747614
C0042109	vitamin a	D014801	11103-57-4	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	thiamine	D013831	59-43-8	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	vitamin e	D014810	1406-18-4	urticaria	MESH:D014581	marker/mechanism	11792017
C0042109	zafirlukast	C062735	107753-78-6	urticaria	MESH:D014581	therapeutic	14512923
C0042109	ziprasidone	C092292	146939-27-7	urticaria	MESH:D014581	marker/mechanism	17446198

FDA approved drug and dosage information(Total Drugs:26)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D014581	claritin	loratadine	10MG	TABLET;ORAL	Over-the-counter	None	Yes	Yes
MESH:D014581	claritin	loratadine	1MG/ML	SYRUP;ORAL	Over-the-counter	None	Yes	Yes
MESH:D014581	claritin	loratadine	10MG	CAPSULE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D014581	loratadine	loratadine	10MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D014581	loratadine	loratadine	1MG/ML	SUSPENSION;ORAL	Over-the-counter	None	Yes	Yes
MESH:D014581	mevacor	lovastatin	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET;ORAL	Discontinued	None	Yes	No
MESH:D014581	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D014581	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D014581	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D014581	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D014581	cipro	ciprofloxacin	400MG/40ML (10MG/ML)	INJECTABLE;INJECTION	Discontinued	None	Yes	No
MESH:D014581	cipro	ciprofloxacin	250MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	No
MESH:D014581	prevacid	lansoprazole	15MG	CAPSULE, DELAYED REL PELLETS;ORAL	Prescription	AB	Yes	No
MESH:D014581	prevacid	lansoprazole	15MG/PACKET	FOR SUSPENSION, DELAYED RELEASE;ORAL	Discontinued	None	No	No
MESH:D014581	prevacid	lansoprazole	15MG	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL	Prescription	None	Yes	No
MESH:D014581	prevacid	lansoprazole	15MG	CAPSULE, DELAYED REL PELLETS;ORAL	Prescription	AB	Yes	No
MESH:D014581	prevacid	lansoprazole	15MG/PACKET	FOR SUSPENSION, DELAYED RELEASE;ORAL	Discontinued	None	No	No
MESH:D014581	prevacid	lansoprazole	15MG	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL	Prescription	None	Yes	No
MESH:D014581	mobic	meloxicam	7.5MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D014581	mobic	meloxicam	7.5MG/5ML	SUSPENSION;ORAL	Prescription	None	Yes	Yes
MESH:D014581	celebrex	celecoxib	100MG	CAPSULE;ORAL	Prescription	AB	Yes	No
MESH:D014581	celebrex	celecoxib	100MG	CAPSULE;ORAL	Prescription	None	No	No
MESH:D014581	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D014581	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D014581	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D014581	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes

FDA labeling changes(Total Drugs:26)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D014581	4/12/2000	claritin	loratadine	Allergic rhinitis/Urticaria	Labeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescence	Labeling	B	-	-	-	Schering	08/14/2000	FALSE'
MESH:D014581	4/12/2000	claritin	loratadine	Allergic rhinitis/Urticaria	Labeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescence	Labeling	B	-	-	-	Schering	08/14/2000	FALSE'
MESH:D014581	4/12/2000	claritin	loratadine	Allergic rhinitis/Urticaria	Labeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescence	Labeling	B	-	-	-	Schering	08/14/2000	FALSE'
MESH:D014581	4/12/2000	claritin	loratadine	Allergic rhinitis/Urticaria	Labeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescence	Labeling	B	-	-	-	Schering	08/14/2000	FALSE'
MESH:D014581	4/12/2000	claritin	loratadine	Allergic rhinitis/Urticaria	Labeling for 2 - 5 year olds including information on dose, PK parameters and AE profile PK parameter in 2-5 year olds given a 5mg dose was comparable to the 10mg dose in children 6 years to adolescence	Labeling	B	-	-	-	Schering	08/14/2000	FALSE'
MESH:D014581	02/14/2002	mevacor	lovastatin	Heterozygous Familial Hypercholesterolemia	New indication in adolescent boys and girls (at least one year post-menarche) 10-17 years of age	Labeling	B	-	-	-	Merck	07/17/2001	FALSE'
MESH:D014581	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D014581	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D014581	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D014581	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D014581	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D014581	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D014581	06/17/2004	prevacid	lansoprazole	Short-term treatment of symptomatic GERD and erosive Esophagitis	Expanded age range to include patients 12 -17 years of age; previously labeled only in pediatric patients 1-11 years of age Safety and effectiveness in pediatric patients	Labeling	B	-	-	-	Tap	07/15/2008	FALSE'
MESH:D014581	06/17/2004	prevacid	lansoprazole	Short-term treatment of symptomatic GERD and erosive Esophagitis	Expanded age range to include patients 12 -17 years of age; previously labeled only in pediatric patients 1-11 years of age Safety and effectiveness in pediatric patients	Labeling	B	-	-	-	Tap	07/15/2008	FALSE'
MESH:D014581	06/17/2004	prevacid	lansoprazole	Short-term treatment of symptomatic GERD and erosive Esophagitis	Expanded age range to include patients 12 -17 years of age; previously labeled only in pediatric patients 1-11 years of age Safety and effectiveness in pediatric patients	Labeling	B	-	-	-	Tap	07/15/2008	FALSE'
MESH:D014581	10/28/2008	prevacid	lansoprazole	Symptomatic GERD in infants	Effectiveness was not established in a 4 week multicenter, double-blind, placebo-controlled study of patients 1 month and < 12 months of age AE profile similar to that observed in adultsInformation on PK parameters in neonates to < 1 year, and clinical studies	Labeling	-	-	B, P	-	Takeda	07/15/2008	FALSE'
MESH:D014581	10/28/2008	prevacid	lansoprazole	Symptomatic GERD in infants	Effectiveness was not established in a 4 week multicenter, double-blind, placebo-controlled study of patients 1 month and < 12 months of age AE profile similar to that observed in adultsInformation on PK parameters in neonates to < 1 year, and clinical studies	Labeling	-	-	B, P	-	Takeda	07/15/2008	FALSE'
MESH:D014581	10/28/2008	prevacid	lansoprazole	Symptomatic GERD in infants	Effectiveness was not established in a 4 week multicenter, double-blind, placebo-controlled study of patients 1 month and < 12 months of age AE profile similar to that observed in adultsInformation on PK parameters in neonates to < 1 year, and clinical studies	Labeling	-	-	B, P	-	Takeda	07/15/2008	FALSE'
MESH:D014581	11/8/2005	mobic	meloxicam	Relief of signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis	Safety and efficacy established in patients 2 years of age and older Clinical studies evaluated doses ranging from 0.125 mg/kg/day to 0.375 mg/kg/day. There was no additional benefit demonstrated by doses above 0.125 mg/kg/day in the clinical trials. The lowest effective dose should be used Adverse events in children were similar to those in adults including skin reactions and gastrointestinal bleed risk Information on dose, PK parameters, AE profile and clinical studies	Labeling	-	-	B, P	-	Boehringer Ingelheim	04/15/2005	FALSE'
MESH:D014581	11/8/2005	mobic	meloxicam	Relief of signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis	Safety and efficacy established in patients 2 years of age and older Clinical studies evaluated doses ranging from 0.125 mg/kg/day to 0.375 mg/kg/day. There was no additional benefit demonstrated by doses above 0.125 mg/kg/day in the clinical trials. The lowest effective dose should be used Adverse events in children were similar to those in adults including skin reactions and gastrointestinal bleed risk Information on dose, PK parameters, AE profile and clinical studies	Labeling	-	-	B, P	-	Boehringer Ingelheim	04/15/2005	FALSE'
MESH:D014581	12/15/2006	celebrex	celecoxib	Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA)	New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs	Labeling	B	-	-	-	Pfizer	08/23/2006	FALSE'
MESH:D014581	12/15/2006	celebrex	celecoxib	Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA)	New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs	Labeling	B	-	-	-	Pfizer	08/23/2006	FALSE'
MESH:D014581	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D014581	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D014581	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D014581	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE